ABSTRACT
Results: Among 190 patients with gestational trophoblastic neoplasia (GTN), two had pure ETT and three had mixed ETT and choriocarcinoma. The median age was 32.5 years. All the patients had localized disease in the uterus. One patient with pure ETT had a recurrence in the ureter 6 years after the initial treatment. Another patient with pure ETT had two full-term deliveries after fertility-sparing surgery. The three patients with mixed tumors had chemotherapy for GTN before their diseases were completely treated by hysterectomy. At a median follow-up of 102 months, all patients survived.

Conclusions: ETT is indolent. Recurrence can happen, but the risk factors are not clear. When patients with GTN fail to respond to chemotherapy, the possibility of mixed GTN should be considered.
Epithelioid trophoblastic tumor (ETT) is rare, with only about 110 cases reported in the literature. 1 Mazur and Kurman 2 first described the entity in 1994, and Shih and Kurman 3 elaborated on it further in 1998. ETT, a tumor derived from chorionic laeve-type extravillous trophoblasts, is characterized by uniform monomorphic nests and cords of mononucleated intermediate trophoblastic cells, which are surrounded by extensive necrosis and are associated with an eosinophilic hyaline-like matrix, creating a "geographical" pattern. 4 Some scholars believed ETT was the result of a malignant transformation from a preexisting placental site nodule (PSN), 5, 6 although it is noteworthy that most PSNs do not progress to ETT, and the former do not require hysterectomy. Nearly half of the ETTs are located in the lower uterine segment, or endocervix, and it is therefore conceivable they may be mistaken as squamous cell carcinoma of the cervix. [7] [8] [9] Most ETTs occur in the reproductive age group, and the average age is 36.1 years (range, 15-48 years). 3 Patients often have symptoms resembling those in placental site trophoblastic tumor (PSTT). Because both types of tumors are slow growing, the patients can be asymptomatic. 1 About 60% to 70% of the patients have abnormal vaginal bleeding, and some may have amenorrhea. 10 About 30% to 50% of the patients have symptoms related to metastasis, such as shortness of breath and hemotypsis. 1, 6 Rarely, they might present with nephrotic syndrome and virilization. There is no unique staging system for PSTT and ETT. Since most PSTT and ETT are diagnosed with the tumor confined inside the uterus, and the serum human chorionic gonadotropin (hCG) level is usually
Results
In total, 190 patients diagnosed with GTN, excluding those with partial and complete hydatidiform moles, were identified during the study period, including two pure ETTs (patients A and B) and three mixed ETTs and choriocarcinoma (CC) (patients C, D, and E). All were Chinese, and the median age at diagnosis was 32.5 years (range, 25-50 years).
All tumors were confined in the uterus, and the median interval from the antecedent pregnancy was 31.8 months (range, 21.6-94.3 months). ETT was not suspected before the initiation of treatment in all patients. Those with mixed ETT and CC had a higher hCG level (median, 1,400 IU/mL; range, 192.2-3,139 IU/L) than those with pure ETT (<0.5 IU/L). Their high hCG level led to a clinical suspicion of pregnancy-related disorders before treatment. The details of their clinical presentations are as follows.
Patient A
Patient A, 32 years old, gravida 3 para 2, had amenorrhea for 1 year after stopping oral contraceptive pills in 2008. She had abdominal pain 2 years later (March 2010), and CT showed a complex mass measuring 8 × 7 × 4 cm in the lower part of the uterus ❚Image 1❚. Laparotomy was performed for suspected malignancy. An 8-cm uterine cystic mass was found intraoperatively, and both ovaries appeared normal. Total abdominal hysterectomy (TAH) was performed. Pathologic examination showed ETT involving the uterine corpus with extensions to the uterine serosa, endocervix, and paracervical adventitia, compatible with FIGO stage I. The mitotic count was two mitotic figures (MFs)/10 high-power fields (hpfs), and the MIB1 proliferative index (Ki-67) was 10%. The time interval between her preceding miscarriage and the diagnosis of ETT was not exactly known but was thought to be within 1 year. The WHO score was estimated to be 3 to 5. She had been followed up, and her hCG level was normal all along. The patient complained of urinary leakage from the vagina in April 2016, about 6 years after the initial diagnosis of GTN, and vesicovaginal fistula was diagnosed by a CT urogram (Image 1). However, positron emission tomography (PET)-CT did not reveal any recurrence. A right ureteric resection and reimplantation were performed in July 2016. Recurrent ETT was found in the ureteric specimen. This tumor was morphologically identical to the primary tumor and expressed AE1/AE3, CD10, E-cadherin, p63, inhibin, and placental alkaline phosphatase. The Ki-67 index was 30% to 40%. The tumor involved surgical margins, and the patient was offered adjuvant chemotherapy but declined. She remained well, and there was no recurrence about 1.5 years after the surgery.
Patient B
Patient B, 25 years old, gravida 1 para 0, had acute abdominal pain for 3 days in May 2010. An ultrasound showed a posterior uterine cystic lesion that measured 11.9 × 10.4 × 8.5 cm. There was no solid component. An emergency laparotomy was performed, during which a cystic mass was found over the posterior uterine serosa extending from the uterine fundus to the pouch of Douglas. It contained old blood. The cyst was excised and was histologically confirmed to be ETT. The mitotic count was two MFs/10 hpfs, and the Ki-67 index was 20%. Microsatellite analysis of the cyst and the patient's blood confirmed that the tumor was gestational in origin. In view of the patient's young age and the desire for fertility preservation, a hysterectomy was not performed; adjuvant chemotherapy was also not given due to the likelihood of a potential poor response. Serial hCG blood tests and MRI did not reveal any recurrence. The patient had a full-term delivery by caesarean section in April 2014 and another full-term normal vaginal delivery in October 2017, about 4 and 7.5 years after her initial diagnosis, respectively.
Patient C
Patient C had previously been reported by our group but is included in the current analysis due to additional follow-up information.
14 This 50-year-old woman, gravida 7 para 4, had a history of molar pregnancy in October 1997. She had persistent vaginal bleeding in December 1997, and her hCG level was raised to 242 IU/L. She was . 15 However, the hCG level rose to 2,600 IU/L 2 months after chemotherapy. An ultrasound showed a 0.9 × 0.7 × 1.1-cm uterine nodule with focal vascular flow. In September 2000, because of the lack of response and possibility of rare GTN, a laparoscopic-assisted vaginal hysterectomy and bilateral salpingo-oophorectomy were performed. The pathology was mixed ETT and CC in which one-third of the tumor was composed of CC. The ETT element had one MF/10 hpfs and a Ki-67 index of less than 1%. No further chemotherapy was given, and she has remained disease free for 17 years.
Patient D
This 34-year-old woman, gravida 4 para 1, had a history of postmolar GTN, which was treated with chemotherapy in mainland China in 1995. She had a full-term delivery by caesarean section in 1998. In January 2006, 11 years after her initial GTN, she complained of vaginal bleeding, and her hCG was elevated to 807 IU/L. A transvaginal scan revealed no gestational sac. A diagnostic laparoscopy was then performed, but no abnormality was found. The suction evacuation yielded endometrium only. Two courses of methotrexate were given for a provisional diagnosis of ectopic pregnancy of unknown location. However, her hCG level was increasing, and PET-CT showed increased uptake inside the uterine cavity bleeding in December 2008, 5 years after the initial diagnosis of GTN, and her hCG level was 3,139 IU/L. An ultrasound showed a 4.7 × 3.8 × 3.6-cm left uterine cornual mass. She was treated with three cycles of low-dose methotrexate for a provisional diagnosis of cornual pregnancy, and her hCG level dropped slowly but remained elevated at 39 IU/L. A laparoscopy was performed in February 2009, during which a 2-cm mass was found in the uterine fundus. The tumor was resected and conversion to a laparotomy was required because of extensive bleeding. The pathologic diagnosis was mixed ETT and CC, with a mitotic count of 1 MF/10 hpfs, and the Ki-67 index was 20%. In March 2009, TAH was performed and residual CC was found. In view of the CC component, two cycles of CHAMOC were completed as consolidation in April 2009. The hCG remained normal, and there was no evidence of recurrence after a follow-up duration of 8 years.
In our current series, the median follow-up for all five patients was 102 months (range, 88-238 months), and all patients survived. The clinical features and pathologic findings of the above patients are listed in ❚Table 1❚ and ❚Table 2❚, respectively.
Discussion
ETT is a rare trophoblastic tumor with its origins in chorion laeve-type extravillous trophoblasts. In the first case series by Shih and Kurman, 3 66.7% of patients with ETT had preceding term pregnancies. However, in the review by Zhang et al, 12 among 45 patients whose obstetrics history was available, 51.1% had undergone abortions, 24.4% had complete hydatidiform moles, 8.9% had invasive moles, 4.4% had experienced ectopic pregnancies, and only 8.9% had achieved term pregnancies. In our series, none of the ETTs were preceded by term pregnancies but by miscarriage (40%; 2/5), abortion (20%; 1/5), ectopic pregnancy (20%; 1/5), and molar pregnancy (10%; 1/5). Unlike the usual clinical presentations reported in the literature, only one of our patients had abnormal vaginal bleeding. The median time interval from the antecedent pregnancies in our series was 31.8 months, which was similar to that reported by Zhang et al, 12 which was 36 months (range, 0-300 months). Two (40%) of five of our patients received chemotherapy prior to surgery too, which was higher than the 14.3% to 20.9% in the literature. 10, 12 ETT can recur late. 6 Zhang et al 12 reported that 19 (30.6%) of 62 patients relapsed, with a median relapse/ metastasis time of 8 months (mean, 21.1 months; range, 1-145 months). 12 Mitotic count in pure ETT is usually about two per 10 hpfs (range, 0-9), and the mean Ki-67 index is 17.7% ± 4.5% (range, 10%-25%). 3, 16 hCG is mildly elevated, where the median is 665 IU/L. 12 It is usually less than 2,500 U/L 17 and only rarely rises to more than 10,000 IU/L. 16 It has been difficult to identify poor prognosticators in ETT due to the small sample size and short follow-up in previous case series. Davis et al 10 showed that an interval from the preceding pregnancy of more than 4 years might be associated with a poor prognosis. Of the three of their seven patients who had an interval of 9 to 22 years from their last pregnancies, two had metastatic disease on diagnosis and had static or progressive disease after chemotherapy. The remaining patient had a hysterectomy for localized disease, but she recurred and had progressive disease despite chemotherapy. Tumor size, tumor necrosis, and cytologic atypia appeared not to have a prognostic value. 6, 18 Shih and Kurman 3 stated that the Ki-67 index was not related to the clinical behavior of ETT in their early series, and the interpretation might be difficult due to the similar morphology between intermediate trophoblasts, cytotrophoblasts, decidua, and smooth muscles. 19 The assessment might also have been obscured by the surrounding immune cells, such as natural killer cells and lymphocytes, which had a high Ki-67 index too. High mitotic activity of more than five MFs/10 hpfs has been shown to correlate with poor outcomes in PSTT. 20 However, its significance is unclear in ETT. 18, 19, 21 For example, the patient in the case report by Coulson et al 21 whose mitotic figure was up to 30 MFs/10 hpfs remained disease free for 15 months after hysterectomy. The patient in the series by Sung et al 18 whose mitotic count was 36 MFs/10 hpfs had stage I disease and was disease-free for 8 years after hysterectomy. It is noteworthy that the assessment and interpretation of mitotic activity and proliferative index could be problematic in tumors among patients who have received preoperative chemotherapy since these parameters are expected to be lower, and comparison with cases without treatment would be difficult. p53 overexpression has been implicated in the development of GTN. 22, 23 Nagai et al 24 found that p53 immunostaining was positive in six (100%) of six patients with metastatic or recurrent PSTT, while it was positive in only one (16.7%) of six patients whose PSTT was confined in the uterus (P = .015), indicating there might be a role of p53 in the disease progression of PSTT, despite a small sample size. Both their patients with ETT and all three patients in Sung et al 18 also had positive p53 immunostaining, but no poor outcomes were observed. The value of a high serum β-hCG level is also controversial. 6, 25 In fact, a high β-hCG level might raise the rare possibility of coexisting CC. 1 The use of chemotherapy alone without hysterectomy might be a risk factor since definitive treatment might be delayed. Zhang et al 12 demonstrated that the use of adjuvant chemotherapy after surgery increased the risk of recurrence compared with surgery alone (P = .005). However, only stage was an independently significant risk factor for overall survival after multivariate analysis (P = .015).
In our cohort, patient D had an interval of more than 4 years from her last pregnancy, extensive tumor necrosis, and vascular invasion, and she received nine cycles of chemotherapy before her hysterectomy. However, she did not experience a recurrence. In contrast, patient A, the only patient who had a recurrence, had no obvious risk factors apart from the presence of tumor necrosis. The recurrence in the ureter was exceptional, and this could not have been detected by PET-CT or intraoperative examination. Since occult distant metastasis could not be excluded, chemotherapy was offered, but the patient declined.
The median overall survival in Zhang et al 12 was 24 months (mean, 29.3 months; range, 6-145 months), and the FIGO stage was the only significant prognosticator for Present but exact depth of invasion was not known survival. Because patients with GTN have lifelong follow-up in our unit, we were able to demonstrate a long overall survival after a median follow-up of 102 months. In addition to the three cases from our center, 14 there have been only 13 other mixed trophoblastic tumors reported in the literature ❚Table 3❚ and ❚Table 4❚. 3, 5, 14, 18, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] The median age was 34 years (range, 15-60 years), and at least six were Asian. It is not known if mixed ETT is more common in Asia, but in general, gestational trophoblastic disease, which includes benign molar pregnancy to the malignant GTN, is more common in Asia than in Western countries. More than half of the patients had abnormal vaginal bleeding. However, none of them could be diagnosed correctly on presentation, which highlighted the diagnostic difficulty. The longest diameter of the uterine tumor for those who did not have preoperative chemotherapy ranged from 2 to 8 cm. Most tumors appeared not to be very mitotically active, and the highest mitotic count was 17 MFs/10 hpfs in a patient with mixed PSTT and CC, 31 and Ki-67 positivity was up to 50% in the CC component in another patient with mixed ETT and PSTT. 35 Tumor necrosis was common. Among 14 patients whose information about their preceding pregnancies was available, the median interval from the antecedent pregnancy was about 26.2 months (range, 14 weeks to 38 years). Six (42.9%) of 14 had a history of molar pregnancies or GTN, and three (21.4%) required systematic chemotherapy.
The median overall survival for the 16 patients was at least 37.5 months (range, 1-231 months). 3, 5, 14, 18, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Four had distant metastasis. Apart from one who defaulted 3 and one who died of disease, 31 the other two patients recurred and yet were alive for at least 1 year after the diagnosis. 26, 27 Pathologic risk factors could not be determined for the two patients who recurred and the one patient who died due to the incompleteness of the pathologic data. Thirteen patients underwent a hysterectomy. Four did not receive chemotherapy, among whom one defaulted and the rest survived up to 84 months without recurrence. Some have suggested that patients with mixed ETT and CC might present in a similar way as those with CC. 32 However, this is not the same in our patients. CHAMOC and EMA-CO have been effective in treating high-risk or recurrent GTN and CC, 15, 36 but our patients C and D did not respond well to these regimens, and their diseases could be controlled only after hysterectomy. These two patients did not receive any adjuvant chemotherapy after hysterectomy, and they have remained disease free for more than 10 years. For patient E, only two cycles of CHAMOC were given postoperatively, and she has not experienced any recurrence for more than 7 years. These patients had a disease course that resembled ETT more than CC. Conventionally, postmolar GTN is diagnosed by hCG surveillance, and patients who fulfill the diagnostic criteria can be readily treated by chemotherapy without a histologic diagnosis. 11 Because of such a high rate of previous molar pregnancy or GTN, as stated above, it is not surprising these patients might have been treated as having recurrent GTN without histologic confirmation since otherwise this might have potentially delayed treatment. However, our findings illustrate that for those who fail to respond to chemotherapy for suspected GTN, histologic evaluation is mandatory, and pathologists specializing in GTN should review the specimen so as not to miss the rare possibility of coexisting ETT or PSTT, which is typically resistant to chemotherapy. Ramondetta et al 26 suggested that for those CCs mixed with either PSTT or ETT, sensitivity to chemotherapy might be related to the ratio of syncytiotrophoblasts and cytotrophoblasts to intermediate trophoblasts. However, the proportion of each component in mixed trophoblastic tumors was not well documented in the literature, and this practice of reporting is not universal among pathologists. It may be worthwhile for the pathologists to report the percentage of different components in mixed GTN so more data can be collected to ascertain whether clinical behavior will follow the more prominent element.
The pathogenesis of mixed ETT is poorly understood. Shih and Kurman 16 proposed that CC, PSTT, and ETT might derive from the same trophoblastic stem cells (ie, cytotrophoblasts), where CC is the most primitive tumor comprising various proportions of neoplastic cytotrophoblasts, syncytiotrophoblasts, and intermediate trophoblasts. 25, 37 PSTT and ETT are more differentiated, where the neoplastic cytotrophoblasts in PSTT differentiate into intermediate trophoblastic cells in an implantation site, and those in ETT differentiate into chorionic-type intermediate trophoblastic cells in the chorion laeve. "Atypical CC," which was later believed to be ETT, had been reported after chemotherapy for proven metastatic CC. [38] [39] [40] Using Shih and Kurman's hypothesis, 16 it was speculated that chemotherapy might allow some CC cells to differentiate into ETT that were less sensitive to chemotherapy because the cells were less primitive in contrast to CC. However, there is still not enough evidence to support that mixed ETT is a result of previous chemotherapy. In Davis et al, 10 two of their patients had elevated hCG and received chemotherapy for a working diagnosis of postmolar GTN before the diagnosis of ETT could be made. They suspected that these patients had mixed tumor with a CC component, and the latter component resolved after chemotherapy, leaving only ETT that could be found on the final histology.
Successful fertility-sparing management has been widely reported in CC. 41 It is estimated that the term live birth rate was higher than 70% after treatment for persistent trophoblastic disease or CC, and there was no increased risk of fetal abnormalities. There are very few case reports on fertility-sparing treatment in PSTT, and the success rate is about 67%. One of our patients (patient B) had fertility-sparing treatment and experienced no recurrence after 89 months of follow-up. Whether this approach is safe for ETT is unknown, and there was only one other report of fertility-sparing treatment. 32 Careful counseling is needed because failed conservative management has been reported, as in the case of PSTT. 42 Until more long-term safety data on fertility-sparing treatment are available, the standard treatment of ETT or mixed ETT is still hysterectomy.
Conclusion
Most ETTs do not respond to chemotherapy, and so hysterectomy is still the mainstay of treatment. Fertilitysparing treatment may be considered, but long follow-up is needed to prove its safety. Mixed trophoblastic tumors are rare, and their clinicopathologic presentations are unclear. Whether their behaviors are related to the proportion of different components and their best treatment option also require more research to define. For those patients with GTN who fail to respond to conventional chemotherapy, a histologic diagnosis with pathologic review is needed to rule out the possibility of mixed GTN.
